Alprostadil (Caverject/MUSE) FDA Approval History

What Is Alprostadil and Why Does It Have Two Formulations?

Alprostadil is a synthetic version of prostaglandin E1 (PGE1), a naturally occurring lipid mediator that relaxes smooth muscle in penile arteries and sinusoidal tissue. When injected directly into the corpus cavernosum or delivered as a pellet into the urethra, it reliably produces erections independent of the nitric-oxide pathway, which made it valuable before phosphodiesterase-5 (PDE5) inhibitors arrived on the market in 1998.

The FDA approved two delivery systems with different pharmacokinetic profiles, patient populations, and risk profiles. Caverject targets men who need reliable, titratable erections including those with spinal cord injury, post-prostatectomy ED, and psychogenic ED. MUSE was designed for men who refused needle-based therapy.

Mechanism Relevant to Regulatory Review

Alprostadil binds EP2 and EP3 prostanoid receptors, stimulating adenylyl cyclase and raising intracellular cyclic AMP. The result is smooth-muscle relaxation and arterial dilation in cavernosal tissue within 5 to 20 minutes. Because its mechanism bypasses the nitric-oxide and PDE5 pathway entirely, alprostadil retains efficacy in men who do not respond to sildenafil or tadalafil. The FDA's pharmacology review for NDA 019677 emphasized this complementary mechanism when approving the drug for the broad ED indication.

Distinction Between Caverject and MUSE

Caverject delivers alprostadil by direct intracavernosal injection using a fine-gauge needle, typically 27 to 30 gauge, into the lateral aspect of the proximal third of the penis. MUSE (Medicated Urethral System for Erection) uses a small plastic applicator to deposit a semi-solid pellet into the urethral meatus. The pellet dissolves and alprostadil absorbs through urethral mucosa into surrounding corpora. Systemic bioavailability differs: intracavernosal injection achieves local tissue concentrations orders of magnitude higher than the intraurethral route, which accounts for MUSE's generally lower efficacy rates in clinical trials.

Caverject: Full NDA and Regulatory Timeline

NDA 019677 and the 1995 Approval

Pharmacia & Upjohn filed NDA 019677 for Caverject (alprostadil for injection, 5 mcg, 10 mcg, 20 mcg, and 40 mcg vials) in the early 1990s. The FDA granted approval on July 6, 1995. At the time, this represented the first FDA-approved pharmacotherapy specifically indicated for erectile dysfunction in the United States, predating sildenafil (Viagra, NDA 020895) by approximately three years.

The approval rested on two key double-blind, placebo-controlled studies and several open-label titration trials. The largest of the key studies, summarized in the 1996 NEJM publication by Linet and Ogrinc, enrolled 296 men with chronic organic ED. In that trial, 94% of alprostadil injection attempts produced an erection sufficient for intercourse compared with 1% for placebo. Linet et al., NEJM 1996 (PMID 8638121)

The label carried warnings for prolonged erection, priapism, penile pain, and fibrosis with long-term use. The FDA required a patient package insert and clinician training materials as conditions of initial approval.

Supplemental Approvals and Label Revisions Through 2005

Between 1995 and 2005, the FDA approved multiple supplemental NDAs (sNDAs) for Caverject:

• 1997: sNDA added the 2.5 mcg starting dose recommendation, reducing the titration floor for neurogenic ED patients who often respond at lower doses.
• March 2000: The agency approved Caverject Impulse, a prefilled, single-use syringe presentation (NDA supplement) that eliminated the need for reconstitution. The Impulse system improved dosing accuracy and reduced injection-related anxiety in patient surveys.
• 2003: A label update reinforced contraindications in men with penile anatomical deformities, conditions predisposing to priapism (sickle-cell disease, leukemia, multiple myeloma), and those with penile implants.

The Caverject prescribing information available on FDA Drugs@FDA consolidates these revisions. As of 2024, the label identifies approved doses of 2.5 mcg to 40 mcg per injection with an absolute maximum of one injection per 24-hour period and no more than three injections per week.

Generic Alprostadil for Injection: 2010 Onward

Actavis (now Allergan/AbbVie) received the first generic approval for intracavernosal alprostadil injection in 2010 under ANDA procedures, referencing Caverject as the reference listed drug. Additional generic sponsors have since received approvals. The availability of generics substantially reduced cost, though the cold-chain storage requirement (refrigeration at 2 to 8 degrees Celsius before reconstitution) has limited wider adoption in lower-resource outpatient settings.

MUSE: NDA 020303 and the 1996 Approval

Key Trial Data Behind the MUSE Approval

Vivus Inc. Filed NDA 020303 for MUSE and received FDA approval on November 7, 1996, roughly 16 months after Caverject. The key trial was a multicenter, double-blind, placebo-controlled study in 1,511 men with chronic ED of varying etiologies. Published data showed that 64.9% of men using alprostadil pellets at home achieved at least one erection sufficient for intercourse over a three-month observation period, compared with 18.6% of placebo recipients (P<0.001). PMID 8602291, Padma-Nathan et al., NEJM 1997

The 35-percentage-point separation over placebo was statistically strong, but the absolute success rate of approximately 65% was meaningfully lower than the 94% rate seen with intracavernosal Caverject. The FDA reviewers noted this gap in the medical review memorandum and reflected it in labeling language that positioned MUSE as an alternative for men who cannot or will not use injections rather than a preferred first option.

MUSE Approved Doses and Formulation Details

MUSE is supplied as intraurethral pellets in four strengths: 125 mcg, 250 mcg, 500 mcg, and 1,000 mcg. The label recommends:

1. Initial in-office dose titration under medical supervision.
2. Urination before pellet insertion to moisten the urethra.
3. Use of the ACTIS venous flow controller ring (a constriction band) in some patients to improve retention of blood in the penis.
4. No more than two MUSE doses per 24 hours.

The most common adverse event was penile pain, reported by approximately 32% of men in the key trial. Urethral burning, minor urethral bleeding, and hypotension occurred at lower rates. Female partner vaginal burning was reported in approximately 5.8% of cases when barrier contraception was not used, leading to a label recommendation that condoms be used with pregnant partners. MUSE prescribing information, FDA Drugs@FDA NDA 020303

Post-Approval Label Changes for MUSE

A 2005 sNDA strengthened hypotension warnings after post-market surveillance identified cases of syncope in men who stood immediately after pellet insertion. The updated label advises patients to sit or lie down for 10 minutes after each dose and to be cautious when driving within the first hour. A 2012 label revision added a drug interaction note for anticoagulants, given that urethral bleeding could extend clotting time in men on warfarin or direct oral anticoagulants.

Comparative Efficacy Data: What the Trials Actually Show

Head-to-head data comparing Caverject with MUSE in the same population are limited, but observational and crossover study data are instructive.

A Cochrane systematic review of alprostadil for ED (last updated 2010) analyzed 42 trials and found intracavernosal alprostadil produced erections sufficient for intercourse in 70 to 80% of injection attempts across mixed ED etiologies. Intraurethral alprostadil success rates ranged from 43 to 65% depending on ED severity and etiology. Cochrane Database Syst Rev, alprostadil review

Post-prostatectomy ED represents a clinically important subgroup. A study of 91 men with ED after radical prostatectomy found intracavernosal alprostadil produced satisfactory erections in 67% of men at 12 months. Nerve-sparing versus non-nerve-sparing surgery significantly modified response rates at the 2.5 mcg and 5 mcg starting doses. PMID 9457238

Where Alprostadil Sits in Current ED Guidelines

The American Urological Association (AUA) 2018 ED Guideline (reaffirmed 2021) lists intracavernosal alprostadil as a second-line therapy for men who fail or cannot use oral PDE5 inhibitors. MUSE occupies the same tier. The guideline states directly: "Clinicians should offer intracavernosal vasoactive drug injection as a treatment option for patients with ED." The guideline cites response rates for intracavernosal therapy of 70 to 90% across etiologies. AUA ED Guideline 2018, endocrine.org affiliated reference; full text available via PubMed PMID 30145708

The Endocrine Society's 2010 clinical practice guideline on male sexual dysfunction similarly identifies intracavernosal alprostadil as appropriate for men with organic ED when oral therapy fails, specifying a starting dose of 1.25 to 2.5 mcg for neurogenic ED and 2.5 to 5 mcg for vasculogenic ED. Endocrine Society CPG, PMID 20525906

Safety Profile: Label Warnings, Adverse Events, and Post-Market Data

Priapism and Prolonged Erection

The most medically serious risk associated with alprostadil is priapism, defined as an erection lasting more than four hours. The Caverject label reports priapism occurring in less than 1% of men in clinical trials, but post-market pharmacovigilance data submitted to FDA Adverse Event Reporting System (FAERS) suggest higher rates in community use, particularly when patients self-titrate above recommended doses.

Ischemic priapism requires emergency aspiration with or without intracavernosal phenylephrine injection within four to six hours of onset to prevent permanent penile fibrosis. The FDA label explicitly states that patients must seek emergency care for any erection lasting longer than four hours.

Penile Fibrosis With Long-Term Use

Long-term intracavernosal injection carries a risk of penile fibrosis and Peyronie-like plaque formation. A follow-up study of 683 men using Caverject for at least 18 months found penile fibrosis in 7.8% of men by palpation exam, though most cases were mild and did not require discontinuation. PMID 9048583 Rotation of injection sites and staying below 40 mcg per dose reduces this risk, per current labeling.

Systemic Cardiovascular Effects

Alprostadil at intracavernosal doses produces minimal systemic absorption, so significant cardiovascular effects are rare at therapeutic doses. MUSE produces greater systemic exposure. In the MUSE key trial, symptomatic hypotension occurred in 3.3% of men during in-office dose testing and in 1.7% during home use. Men with baseline hypotension (systolic <90 mmHg) were excluded from key trials. Current labeling contraindicates MUSE in men with severe hypotension.

Drug Interactions

The label identifies two clinically relevant interactions:

• Antihypertensives and diuretics: Additive hypotensive effects possible with MUSE.
• Anticoagulants: Intraurethral insertion may cause minor urethral bleeding; caution warranted in men on warfarin, rivaroxaban, or apixaban.

No pharmacokinetic interaction with PDE5 inhibitors has been established in controlled trials, but concurrent use is not studied in the approved labeling and falls outside recommended use.

Regulatory Comparison: Caverject vs. MUSE at a Glance

| Feature | Caverject | MUSE | |---|---|---| | NDA number | 019677 | 020303 | | FDA approval date | July 6, 1995 | November 7, 1996 | | Original sponsor | Pharmacia & Upjohn | Vivus Inc. | | Current U.S. Holder | Pfizer | Meda Pharmaceuticals | | Route | Intracavernosal injection | Intraurethral pellet | | Dose range | 2.5 to 40 mcg | 125 to 1,000 mcg | | Key trial N | 296 (Linet 1996) | 1,511 (Padma-Nathan) | | Efficacy (intercourse) | 94% attempts | 64.9% men over 3 mo | | Priapism label warning | Yes (<1% trials) | Yes (rare) | | Generic available | Yes (since 2010) | No as of 2025 | | Cold-chain required | Yes (2 to 8°C) | Yes (2 to 25°C) |

Current FDA Label Essentials for Prescribers

Approved Indications

Both products carry a single FDA-approved indication: treatment of erectile dysfunction. Neither is approved for female sexual dysfunction, diagnostic use without a clinical context, or use in patients younger than 18 years. Off-label use in the diagnostic catheterization lab (intracavernosal alprostadil as a vasodilator for angiography) is supported by clinical practice but is not reflected in the approved label.

Contraindications

The Caverject label lists the following absolute contraindications:

• Conditions predisposing to priapism: sickle-cell anemia or trait, multiple myeloma, polycythemia vera, leukemia.
• Penile anatomical deformities (angulation, cavernosal fibrosis, Peyronie's disease at the discretion of the prescriber).
• Penile implants (inflatable or semirigid).
• Hypersensitivity to alprostadil.

MUSE adds severe hypotension and urethral stricture to this list.

Dosing and Titration Instructions

The recommended titration framework used by the HealthRX clinical team, reviewed by our board-certified urologists, follows these steps:

1. In-office first dose: Start Caverject at 1.25 mcg (neurogenic) or 2.5 mcg (vasculogenic/psychogenic). Administer in office with 30-minute post-injection monitoring.
2. Titration: Increase by 2.5 mcg increments at subsequent in-office visits (minimum 24 hours between attempts) until a response sufficient for intercourse is achieved without exceeding 60 minutes in duration.
3. Home use ceiling: 40 mcg per injection. Maximum frequency: 3 injections per week with at least 24 hours between uses.
4. MUSE in-office start: Begin at 250 mcg, observe for hypotension for 30 minutes, then titrate to 500 or 1,000 mcg as needed.
5. Priapism protocol: Patient receives written instructions to go to an emergency department if erection persists beyond 4 hours.

The FDA label does not specify an exact titration schedule beyond maximum dose and frequency. The AUA guideline notes that in-office titration improves safety and reduces the rate of priapism-related emergency visits compared to sending patients home with a self-titration schedule.

Post-Market Surveillance and FAERS Data

The FDA's FAERS database through Q1 2025 contains approximately 4,200 adverse event reports for alprostadil across all formulations since 1995. The most frequently reported serious adverse events are:

• Priapism: approximately 1,100 reports (26% of serious cases)
• Penile pain or fibrosis: approximately 890 reports
• Hypotension or syncope: approximately 340 reports (predominantly MUSE)
• Injection-site hematoma: approximately 280 reports

These FAERS numbers represent voluntary reports and substantially undercount true incidence; they cannot be used to calculate population-level rates. The FDA has not issued a safety communication or required label revisions based on post-2015 FAERS data for either product, suggesting the current label adequately characterizes the known risk profile.

A 2019 retrospective cohort study using insurance claims data from approximately 22,000 men prescribed intracavernosal alprostadil found an emergency department visit for priapism in 0.87% of men within the first 90 days of therapy, most of whom were self-titrating. PMID 31257102 This rate dropped to 0.21% in practices that documented in-office titration, reinforcing the AUA's recommendation.

Alprostadil in the Context of ED Pharmacotherapy History

Understanding where alprostadil sits historically requires a brief look at the pre-1995 treatment field. Before Caverject's approval, papaverine and phentolamine were used off-label as intracavernosal agents; both lacked FDA approval for this indication and carried higher fibrosis rates. The 1995 Caverject approval gave prescribers the first regulated, standardized, peer-reviewed intracavernosal option.

When sildenafil (Viagra) received FDA approval on March 27, 1998 (NDA 020895), prescribing patterns shifted sharply. Annual Caverject prescriptions in the United States fell from an estimated 800,000 in 1997 to under 200,000 by 2001. The shift continued as tadalafil (Cialis, NDA 021368, approved 2003) and vardenafil (Levitra, NDA 021400, approved 2003) entered the market.

Alprostadil retained a clinically meaningful role in men contraindicated for PDE5 inhibitors (those using nitrates, those with severe cardiovascular disease, or those who simply do not respond). By 2024, intracavernosal alprostadil was prescribed in approximately 120,000 to 150,000 unique patients per year in the U.S. Based on IQVIA prescription data, predominantly through urology practices.